Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced its participation in two upcoming virtual healthcare investor conferences in November 2021. The Jefferies London Healthcare Conference will feature a pre-recorded fireside chat available on November 18, 2021, starting at 3:00 am ET. Additionally, management will engage in a virtual fireside chat at Ophthalmology Day at BTIG on November 30, 2021, at 10:00 am ET. Kala is known for its innovative therapies for eye diseases, including EYSUVIS® and INVELTYS®. For more details, visit kalarx.com.

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in November 2021:

Jefferies London Healthcare Conference
A pre-recorded fireside chat will be made available on the company’s website beginning Thursday, November 18, 2021 at 3:00 am ET/8:00 am GMT. Management will also be available for virtual one-on-one meetings on that date.

To access the webcast and subsequent archived recording of the Jefferies fireside chat, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

Ophthalmology Day at BTIG
Management will participate in a virtual fireside chat moderated by Tom Shrader, PhD, CFA, BTIG Biotechnology Analyst at 10:00am ET and host virtual one-on-one meetings on Tuesday, November 30, 2021.  

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

What events will KALA participate in during November 2021?

Kala Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 18, 2021, and Ophthalmology Day at BTIG on November 30, 2021.

When will the KALA fireside chat be available?

The KALA fireside chat from the Jefferies London Healthcare Conference will be available on November 18, 2021, starting at 3:00 am ET.

What therapies does KALA focus on?

Kala Pharmaceuticals specializes in innovative therapies for eye diseases, including EYSUVIS® and INVELTYS®.

How can investors access KALA's events?

Investors can access KALA's events by visiting the 'Events' section on their website at kalarx.com.

What is the purpose of the BTIG event for KALA?

The BTIG event will include a fireside chat and virtual one-on-one meetings for prospective and existing BTIG clients.